Hashimoto 橋本氏甲狀腺炎

COND-hashimoto

2

interventions reviewed

B

top legacy tier

1

counter-evidence

B Preliminary 1

Published with Warning 🚨 High market risk

D Counter-evidence 1

Insufficient Evidence ⚠️ Moderate market risk